1. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402.
Google Scholar | Crossref | Medline2. Huang, DQ, El-Serag, HB, Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18: 223–238.
Google Scholar | Crossref | Medline3. Orci, LA, Sanduzzi-Zamparelli, M, Caballol, B, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. Epub ahead of print 28 May 2021. DOI: 10.1016/j.cgh.2021.05.002.
Google Scholar | Crossref | Medline4. Rosato, V, Masarone, M, Dallio, M, et al. NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome. Int J Environ Res Public Health 2019; 16: 3415.
Google Scholar | Crossref5. Gastaldelli, A, Cusi, K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep 2019; 1: 312–328.
Google Scholar | Crossref | Medline6. Yki-Järvinen, H . Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–910.
Google Scholar | Crossref | Medline7. Younossi, ZM, Koenig, AB, Abdelatif, D, et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
Google Scholar | Crossref | Medline8. Younossi, Z, Anstee, QM, Marietti, M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20.
Google Scholar | Crossref | Medline9. Younossi, ZM, Golabi, P, De Avila, L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019; 71: 793–801.
Google Scholar | Crossref | Medline10. VanWagner, LB, Armstrong, MJ. Lean NAFLD: a not so benign condition? Hepatol Commun 2018; 2: 5–8.
Google Scholar | Crossref | Medline11. Ren, TY, Fan, JG. What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol 2021; 18: 289–290.
Google Scholar | Crossref | Medline12. Francque, S, Wong, VW. NAFLD in lean individuals: not a benign disease. Gut. Epub ahead of print 12 March 2021. DOI: 10.1136/gutjnl-2021-324162.
Google Scholar | Crossref13. Chandrasekharan, K, Alazawi, W. Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy. Front Pharmacol 2019; 10: 1413.
Google Scholar | Crossref | Medline14. Stefan, N, Häring, HU, Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7: 313–324.
Google Scholar | Crossref | Medline15. Pirola, CJ, Sookoian, S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology 2015; 62: 1742–1756.
Google Scholar | Crossref | Medline16. Lauridsen, BK, Stender, S, Kristensen, TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J 2018; 39: 385–393.
Google Scholar | Crossref | Medline17. Wong, RJ, Aguilar, M, Cheung, R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547–555.
Google Scholar | Crossref | Medline18. Adam, R, Karam, V, Cailliez, V, et al. 2018 Annual report of the European liver transplant registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293–1317.
Google Scholar | Crossref | Medline19. Targher, G, Byrne, CD, Lonardo, A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65: 589–600.
Google Scholar | Crossref | Medline20. Kasper, P, Martin, A, Lang, S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021; 110: 921–937.
Google Scholar | Crossref | Medline21. Wu, S, Wu, F, Ding, Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016; 6: 33386.
Google Scholar | Crossref | Medline22. De Block, CE, De Leeuw, IH, Van Gaal, LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005; 28: 1649–1655.
Google Scholar | Crossref | Medline23. Priya, G, Kalra, S. A review of insulin resistance in type 1 diabetes: is there a place for adjunctive metformin. Diabetes Ther 2018; 9: 349–361.
Google Scholar | Crossref | Medline24. De Vries, M, Westerink, J, Kaasjager, K, et al. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105: 3842–3853.
Google Scholar | Crossref25. Šimonienė, D, Platu¯kiene, A, Prakapienė, E, et al. Insulin resistance in type 1 diabetes mellitus and its association with patient’s micro- and macrovascular complications, sex hormones, and other clinical data. Diabetes Ther 2020; 11: 161–174.
Google Scholar | Crossref | Medline26. Chillarón, JJ, Goday, A, Flores-Le-Roux, JA, et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94: 3530–3534.
Google Scholar | Crossref | Medline27. Kilpatrick, ES, Rigby, AS, Atkin, SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: ‘double diabetes’ in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707–712.
Google Scholar | Crossref | Medline28. Pambianco, G, Costacou, T, Orchard, TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007; 30: 1248–1254.
Google Scholar | Medline29. Popa, SG, Simion, AM, Soare, M, et al. Insulin resistance and hepatic steatosis in type 1 diabetes mellitus and their association with diabetic chronic complications. Minerva Endocrinol. Epub ahead of print 2 October 2020. DOI: 10.23736/S0391-1977.20.03290-3.
Google Scholar | Crossref | Medline30. De Block, CEM, Shivalkar, B, Goovaerts, W, et al. Coronary artery calcifications and diastolic dysfunction versus visceral fat area in type 1 diabetes: VISCERA study. J Diabetes Complications 2018; 32: 271–278.
Google Scholar | Crossref | Medline31. Mantovani, A, Mingolla, L, Rigolon, R, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol 2016; 225: 387–391.
Google Scholar | Crossref | Medline32. Targher, G, Mantovani, A, Pichiri, I, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014; 37: 1729–1736.
Google Scholar | Crossref | Medline33. Tilg, H, Adolph, TE, Moschen, AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology 2021; 73: 833–842.
Google Scholar | Crossref | Medline34. Ipsen, DH, Lykkesfeldt, J, Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018; 75: 3313–3327.
Google Scholar | Crossref | Medline35. Regnell, SE, Lernmark, Å. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011; 8: 454–467.
Google Scholar | Crossref | Medline36. Im, SS, Kang, SY, Kim, SY, et al. Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes 2005; 54: 1684–1691.
Google Scholar | Crossref | Medline37. Horton, JD, Goldstein, JL, Brown, MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–1131.
Google Scholar | Crossref | Medline38. Bergsten, P . Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev 2000; 16: 179–191.
Google Scholar | Crossref | Medline39. Alwahsh, SM, Gebhardt, R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol 2017; 91: 1545–1563.
Google Scholar | Crossref | Medline40. Basaranoglu, M, Basaranoglu, G, Bugianesi, E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr 2015; 4: 109–116.
Google Scholar | Medline41. Vos, MB, Lavine, JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013; 57: 2525–2531.
Google Scholar | Crossref | Medline42. Chatrath, H, Vuppalanchi, R, Chalasani, N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32: 22–29.
Google Scholar | Crossref | Medline43. Vergès, B . Lipid disorders in type 1 diabetes. Diabetes Metab 2009; 35: 353–360.
Google Scholar | Crossref | Medline44. Kitade, H, Chen, G, Ni, Y, et al. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients 2017; 9: 387.
Google Scholar | Crossref | Medline45. Brownlee, M . The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615–1625.
Google Scholar | Crossref | Medline46. Kaul, K, Apostolopoulou, M, Roden, M. Insulin resistance in type 1 diabetes mellitus. Metabolism 2015; 64: 1629–1639.
Google Scholar | Crossref | Medline47. Xu, X, So, JS, Park, JG, et al. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 2013; 33: 301–311.
Google Scholar | Crossref | Medline48. Azzout-Marniche, D, Bécard, D, Guichard, C, et al. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000; 350: 389–393.
Google Scholar | Crossref | Medline49. Chadt, A, Al-Hasani, H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch 2020; 472: 1273–1298.
Google Scholar | Crossref | Medline50. Hatting, M, Tavares, CDJ, Sharabi, K, et al. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci 2018; 1411: 21–35.
Google Scholar |